Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
11.08.2007
QALY time - Again!
... the never ending QALY discussion has been revisited by the BMJ in summer. Looks like with all the talk and difficulties associated around QALYs its time to bring some more economics back into the field and grow out a bit of the doctrin of biostatistics. In that regard a highly recommend the article from John FP Bridges "What can economics add to health technology assessment? Please not just another cost-effectiveness analysis!" http://www.future-drugs.com/doi/abs/10.1586/14737167.6.1.19
No comments:
Post a Comment